World BI’s Drug Discovery Innovation Programme (DDIP) EU 2026 brings together leaders from pharma, biotech, academia, and emerging technology companies to address the most critical challenges in early-stage drug discovery and translational science.

From small molecules and biologics to AI-driven discovery, biomarker development, and novel therapeutic platforms, DDIP is designed to deliver scientific depth, real-world case studies, and future-facing insights that accelerate the journey from idea to impact.

Swiss Biotech Association members benefit from a 20% discount. Reach out to obtain the discount code before registering.